Insmed Incorporated
NASDAQ:INSMBiotechnology
-$2.73 today
- Market cap
- $26.28B
- Beta
- 0.77
- P/E (TTM)
- -17.4
- EPS (TTM)
- -$5.49
Volume 1.94M
Average 3.31M
INSM Other Non-current Assets
Long-term assets not reported separately.
Insmed IncorporatedNASDAQ: INSM
Other Non-current Assets · Q2 FY2026 · quarter ended Jun 2026
Other non-current assets rises 17.6% from a year ago
Other non-current assets stood at $104.44M at the end of Q2 FY2026, up 17.6% from a year earlier and up 5.2% from the prior quarter. Over 3 fiscal years it compounded at +8.6% a year.
Context
- Other non-current assets amounted to 5.0% of total assets at the end of Q2 FY2026, up 1.4 pp from a year earlier.
- Other non-current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other non-current assets keeps rising in the next quarterly balance sheet after a +17.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 97.38M USD
- Year-over-year change
- +4.5%
- 4-year CAGR
- +17.6%
| Period | Period end | Other Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 97.38M | +4.5% |
| FY2024 | 2024-12-31 | 93.23M | -3.5% |
| FY2023 | 2023-12-31 | 96.57M | +26.9% |
| FY2022 | 2022-12-31 | 76.1M | +49.3% |
| FY2021 | 2021-12-31 | 50.99M | — |
Other Non-current Assets vs competitors
How INSM compares with its peers on the latest reported figures
- INSM's Jun 2026 other non-current assets of $104.44M is the 2nd highest of the 4 companies compared; the peer median is $37.93M.
- Its year-over-year change of +17.6% is the highest of 4, against a peer median of +0.5%.
- Other non-current assets amounts to 5.0% of total assets for INSM, versus a peer median of 5.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $239.5M | +2.7% | +19.9% | 3.3% | |
| Jun 2026 | $104.44M | +17.6% | +8.6% | 5.0% | |
| Jun 2026 | $37.93M | +0.5% | +101.5% | 7.3% | |
| Mar 2026 | $25.3M | -84.1% | -51.9% | 5.4% | |
AVLNAvalyn Pharma Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding INSM) | $37.93M | +0.5% | +19.9% | 5.4% | |
Competitors are the stored peer set for INSM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 716.78M | 1.07B | 482.37M | 555.03M | 510.45M |
| Short-term Investments | 0 | 74.24M | 298.07M | 878.8M | 919.6M |
| Net Receivables | 24.35M | 29.71M | 41.19M | 52.01M | 140.86M |
| Inventory | 67.01M | 69.92M | 83.25M | 98.58M | 132.07M |
| Other Current Assets | 0 | 25.47M | 24.18M | 37.25M | 91.24M |
| Total Current Assets | 837.04M | 1.27B | 929.06M | 1.62B | 1.79B |
| Property, Plant & Equipment (Net) | 95.52M | 102.08M | 104.39M | 115.58M | 139.21M |
| Goodwill | 136.11M | 136.11M | 136.11M | 136.11M | 136.11M |
| Intangible Assets | 73.81M | 68.76M | 63.7M | 58.65M | 97.65M |
| Long-term Investments | 50.04M | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 50.99M | 76.1M | 96.57M | 93.23M | 97.38M |
| Total Non-current Assets | 406.47M | 383.05M | 400.77M | 403.57M | 470.35M |
| Total Assets | 1.24B | 1.66B | 1.33B | 2.03B | 2.26B |
| Account Payables | 35.78M | 50.46M | 65.39M | 73.03M | 79.91M |
| Short-term Debt | 0 | 0 | 0 | 16.5M | 19.26M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 33.46M | 42.74M | 55.63M | 127.69M | 258.19M |
| Total Current Liabilities | 135.17M | 190.24M | 225.63M | 297.53M | 468.87M |
| Long-term Debt | 566.59M | 1.13B | 1.16B | 1.26B | 716M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 95.74M | 208.5M | 242.78M | 144.7M | 307.81M |
| Total Non-current Liabilities | 697.87M | 1.38B | 1.44B | 1.44B | 1.06B |
| Total Liabilities | 833.04M | 1.57B | 1.66B | 1.74B | 1.53B |
| Common Stock | 1.19M | 1.36M | 1.48M | 1.79M | 2.14M |
| Retained Earnings | (2.27B) | (2.7B) | (3.45B) | (4.36B) | (5.64B) |
| Accumulated OCI | 968K | 756K | (745K) | (2.29M) | 1.46M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 410.47M | 87.95M | (331.92M) | 285.38M | 738.98M |
| Total Debt | 612.27M | 1.18B | 1.2B | 1.31B | 768.16M |
| Net Debt | (104.51M) | 103.83M | 721.62M | 759.09M | 257.71M |
Insmed Incorporated
NASDAQ:INSM
Intrinsic Alpha fair value
Locked
Current Price
$119.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.